Remus Pharmaceuticals (NSE:REMUS) Forward Dividend Yield %: 0.13% (As of Jun. 29, 2026)


NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
55 GF Score
Price ₹793.70
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Forward Dividend Yield %?

Remus Pharmaceuticals NSE:REMUS -1.02% 55 Forward Dividend Yield % is 0.13% as of Jun. 29, 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 68 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 98.53% on this metric.

As of today (2026-06-29), the Forward Annual Dividend Yield of Remus Pharmaceuticals is 0.13%.

As of today (2026-06-29), the Trailing Annual Dividend Yield of Remus Pharmaceuticals is 0.13%.

NSE:REMUS's Forward Dividend Yield % is ranked worse than
98.53% of 68 companies
in the Medical Distribution industry
Industry Median: 2.93 vs NSE:REMUS: 0.13

Remus Pharmaceuticals's Dividends per Share for the six months ended in Mar. 2026 was ₹0.50.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Remus Pharmaceuticals  (NSE:REMUS) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Remus Pharmaceuticals Forward Dividend Yield % Related Terms


NSE:REMUS vs MCK, CAH, COR: Forward Dividend Yield % Comparison

For the Medical Distribution subindustry, Remus Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Remus Pharmaceuticals Forward Dividend Yield % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Remus Pharmaceuticals's Forward Dividend Yield % falls into.


NSE:REMUS
55GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Remus Pharmaceuticals Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
INR 0.5000002025-11-142025-11-140000-00-00Cash Dividendsemi-annuallyINR:INR 1.000000
INR 0.5000002025-09-182025-09-180000-00-00Cash Dividendsemi-annuallyINR:INR 1.000000

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Remus Pharmaceuticals's Forward Annual Dividend Yield (%) for Today is calculated as

Forward Annual Dividend Yield=Forward Full Year Dividend/Current Share Price
=/793.70
=0.00 %

Current Share Price is ₹793.70.
Remus Pharmaceuticals's Dividends per Share for the forward twelve months is calculated as * = .

Remus Pharmaceuticals's Trailing Annual Dividend Yield (%) for Today is calculated as

Trailing Annual Dividend Yield=Most Recent Full Year Dividend/Current Share Price
=1/793.70
=0.13 %

Current Share Price is ₹793.70.
Remus Pharmaceuticals's Dividends per Share for the trailing twelve months (TTM) ended in Today is ₹1.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Dividend Yield % of 0.13% mean?
Remus Pharmaceuticals (NSE:REMUS) has a Forward Dividend Yield % of 0.13% as of Jun. 29, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Remus Pharmaceuticals and its competitors. According to the industry distribution chart, Remus Pharmaceuticals ranks #67 out of 68 companies in the Medical Distribution industry, placing it in the top 98.5%.
Is Remus Pharmaceuticals' Forward Dividend Yield % too high?
Remus Pharmaceuticals' current Forward Dividend Yield % is 0.13%. The Medical Distribution industry median Forward Dividend Yield % is 2.93. Remus Pharmaceuticals' value of 0.13% is 95.6% below this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #67 out of 68 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Forward Dividend Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #67 out of 68 companies for Forward Dividend Yield %. This places Remus Pharmaceuticals in the lower half of its industry. The industry median Forward Dividend Yield % is 2.93. Remus Pharmaceuticals' value of 0.13% is 95.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Distribution company?
The median Forward Dividend Yield % among Medical Distribution companies is 2.93, based on 68 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current Forward Dividend Yield % of 0.13% is 95.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Forward Dividend Yield % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Forward Dividend Yield % is 0.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹793.70 — trading 61.7% below its estimated fair value. The current Forward Dividend Yield % is 0.13% and 95.6% below the Medical Distribution industry median of 2.93. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Forward Dividend Yield % is 0.13% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹793.70 is trading 61.7% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Forward Dividend Yield %: 0.13%
  • GF Value™: ₹2,071.36 vs. price of ₹793.70 (61.7% below fair value)
  • GF Score™: 55/100 with 2 warning signs
  • Industry Position: 95.6% below the Medical Distribution median (#67 of 68)

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score

Get the complete analysis for NSE:REMUS

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹793.70
Price
₹2,071.36
GF Value